Gender-affirming hormone therapy associated with increased serum creatinine in transgender men, but not transgender women<\/em><\/p>\n<\/h3>\n <\/b><\/p>\n <\/b><\/p>\n WEDNESDAY, Aug. 17, 2022 (HealthDay News) — Gender-affirming hormone therapy (GAHT) is associated with increased serum creatinine in transgender men, but not in transgender women, according to a systematic review and meta-analysis published online Aug. 16 in the Clinical Journal of the American Society of Nephrology<\/em>.\n<\/p>\n \n\tEmily Krupka, R.N., from Seven Oaks General Hospital in Winnipeg, Canada, and colleagues conducted a systematic review to characterize the change in serum creatinine, other kidney function biomarkers, and glomerular filtration rate in transgender persons initiating masculinizing and feminizing GAHT. Twenty-six studies met the inclusion criteria, including nine that recruited 488 and 593 transgender men and women, respectively, whose data were included in a meta-analysis.\n<\/p>\n \n\tThe researchers identified heterogeneity in study design, population, GAHT routes, and dosing. Serum creatinine increased by 0.15 mg\/dL in 370 transgender men and decreased by 0.05 mg\/dL in 361 transgender women at 12 months after initiating GAHT. The impact of GAHT on albuminuria, proteinuria, cystatin C, or measured glomerular filtration rate was not reported in any study.\n<\/p>\n \n\t“GAHT increases serum creatinine to a clinically significant degree in transgender men but does not significantly affect serum creatinine in transgender women,” the authors write. “Awareness of the serum creatinine trajectory post-GAHT is important to frame the need for diagnostic testing for acute kidney injury or chronic kidney disease and nephrology consultation.”<\/p>\n \n\tSeveral authors disclosed financial ties to the biopharmaceutical industry.\n<\/p>\n \n\tAbstract\/Full Text (subscription or payment may be required)<\/a>\n<\/p>\n \n\tEditorial (subscription or payment may be required)<\/a>\n<\/p>\n <\/i><\/p>\n